Table 1.
Patient demographic and baseline characteristics (SAF)
| Characteristic | CAD106 150 μg (n = 69) | CAD106 450 μg (n = 37) | CAD106 total (n = 106) | Placebo (n = 15) |
|---|---|---|---|---|
| Sex, n (%) | ||||
| Male | 37 (53.6) | 13 (35.1) | 50 (47.2) | 7 (46.7) |
| Female | 32 (46.4) | 24 (64.9) | 56 (52.8) | 8 (53.3) |
| Age, years | ||||
| Mean (SD) | 67.7 (9.0) | 66.3 (9.4) | 67.2 (9.1) | 68.0 (8.4) |
| Age group, n (%) | ||||
| <65 | 26 (37.7) | 13 (35.1) | 39 (36.8) | 5 (33.3) |
| 65–75 | 27 (39.1) | 17 (45.9) | 44 (41.5) | 6 (40.0) |
| >75 | 16 (23.2) | 7 (18.9) | 23 (21.7) | 4 (26.7) |
| Race, n (%) | ||||
| Caucasian | 67 (97.1) | 37 (100.0) | 104 (98.1) | 14 (93.3) |
| Asian | 1 (1.4) | 0 | 1 (0.9) | 1 (6.7) |
| Other | 1 (1.4) | 0 | 1 (0.9) | 0 |
| Years of education | ||||
| Mean (SD) | 12.3 (3.9) | 12.4 (5.1) | 12.3 (4.3) | 12.9 (5.4) |
| Baseline MHIS, n (%) | ||||
| 0 | 37 (53.6) | 25 (67.6) | 62 (58.5) | 8 (53.3) |
| 1 | 25 (36.2) | 11 (29.7) | 36 (34.0) | 6 (40.0) |
| 2 | 6 (8.7) | 0 | 6 (5.7) | 1 (6.7) |
| 3 | 1 (1.4) | 1 (2.7) | 2 (1.9) | 0 |
| Baseline MMSE | ||||
| Mean (SD) | 22.8 (2.2) | 23.2 (2.2) | 22.1 (2.2) | 22.9 (1.9) |
| Time since first AD symptom was noticed by patient/caregiver (years) | ||||
| Mean (SD) | 4.1 (2.6) | 3.9 (2.2) | 4.0 (2.5) | 3.8 (3.5) |
| Median (range) | 4 (1–12) | 4 (1–10) | 4 (1–12) | 3 (1–15) |
| Time since first AD symptom was diagnosed by physician (years) | ||||
| Mean (SD) | 1.6 (1.5) | 1.5 (1.3) | 1.6 (1.5) | 1.9 (2.8) |
| Median (range) | 1 (0–8) | 1 (0–5) | 1 (0–8) | 1 (0–11) |
| APOE e4 carrier status, n (%) | ||||
| Missing | 8 | 12 | 20 | 0 |
| Non ε4∗ | 18 (29.5) | 8 (32.0) | 26 (30.2) | 6 (40.0) |
| One ε4 allele∗ | 29 (47.5) | 15 (60.0) | 44 (51.2) | 5 (33.3) |
| Two ε4 alleles∗ | 14 (23.0) | 2 (8.0) | 16 (18.6) | 4 (26.7) |
Abbreviations: SAF, safety analysis set; SD, standard deviation; MHIS, Modified Hachinski Ischemic Score; MMSE, Mini–Mental State Examination; AD, Alzheimer's disease; APOE ε4, apolipoprotein E ε4 allele.
∗
Percentage based on the number of patients genotyped.